Subscribe To

Price Alert Latest News Economic Calendar News

ESALY / Eisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call Transcript

Eisai Co., Ltd. (OTCPK:ESALY) Q1 2023 Earnings Conference Call August 5, 2022 3:00 AM ET Company Participants Tatsuyuki Yasuno - SVP, CFO & Chief IR Officer Ivan Cheung - SVP, Global Alzheimer's Disease Officer, President, Americas Region Chairman & CEO, Eisai Inc. Takashi Owa - SVP, President & Chief Discovery Officer of Oncology Business Group Conference Call Participants Motoya Kohtani - Nomura Securities Hidemaru Yamaguchi - Citigroup Seiji Wakao - JPMorgan Fumiyoshi Sakai - Credit Suisse Securities Stephen Barker - Jefferies Takashi Akahane - Tokai Tokyo Research Center Unidentified Company Representative [Foreign Language] [Interpreted] Now it's time to start the financial results briefing session for the first quarter of FY 2022 of Eisai Company Limited. Read More

Demo Live Account See Partner Details

Content Topics

Eisai

Co

Ltd

ESALY

Management

2023

Results

Earnings

esaly

Transcript

Stock

Posted: Aug 6 2022, 13:08

Author Name: Seeking Alpha

ESALY News

By PRNewsWire
March 23, 2023

Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer

Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Or

By CNBC
March 6, 2023

FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July

Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.

By CNBC
February 17, 2023

Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage

Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years.

By Yahoo Finance
February 13, 2023

Alzheimer's drug Leqembi: Eisai U.S. president

Eisai U.S. President Ivan Cheung joins Yahoo Finance Live to discuss the latest news surrounding Alzheimer's treatment with Leqembi.

By Seeking Alpha
February 6, 2023

Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript

Eisai Co., Ltd. (OTCPK:ESALF) Q3 2022 Earnings Conference Call February 6, 2023 3:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice Preside

By Reuters
January 6, 2023

Eisai files for full FDA approval for Alzheimer's drug Leqembi

Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its

By CNBC Television
January 6, 2023

CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval

CNBC's Meg Tirrell talks to Ivan Cheung, Eisai U.S. CEO on the company's Alzheimer's drug receiving approval from the FDA today. With CNBC's Tyler Mat

By Yahoo Finance
January 6, 2023

FDA approves Biogen-Eisai Alzheimer's drug, China in talks to make Pfizer Paxlovid generic

Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative Alzheimer's treatment drug and China's pla

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.